Large Cell Neuroendocrine Carcinoma Clinical Trials

2 recruiting

Large Cell Neuroendocrine Carcinoma Trials at a Glance

10 actively recruiting trials for large cell neuroendocrine carcinoma are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 1 with 7 trials, with the heaviest enrollment activity in Seattle, New York, and Lexington. Lead sponsors running large cell neuroendocrine carcinoma studies include Legend Biotech USA Inc, M.D. Anderson Cancer Center, and Centre Leon Berard.

Browse large cell neuroendocrine carcinoma trials by phase

Treatments under study

About Large Cell Neuroendocrine Carcinoma Clinical Trials

Looking for clinical trials for Large Cell Neuroendocrine Carcinoma? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Large Cell Neuroendocrine Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Large Cell Neuroendocrine Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled579 locationsNCT03866382
Recruiting
Phase 1Phase 2

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Cervical CancerMelanomaBladder Cancer+6 more
University of Arizona30 enrolled2 locationsNCT06814496
Recruiting
Phase 1Phase 2

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Large Cell Neuroendocrine CarcinomaLarge Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Molecular Partners AG138 enrolled3 locationsNCT07278479
Recruiting
Phase 1

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Large Cell Neuroendocrine Carcinoma of the LungSmall Cell Lung CarcinomaNeuroendocrine Prostate Cancer+1 more
Novartis Pharmaceuticals116 enrolled5 locationsNCT07006727
Recruiting

Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix

Stage III Cervical Cancer AJCC v8Stage IIIA Cervical Cancer AJCC v8Stage IIIB Cervical Cancer AJCC v8+19 more
M.D. Anderson Cancer Center750 enrolled1 locationNCT04723095
Recruiting
Phase 1

A Study of FZ-AD005 in Patients With Advanced Solid Tumors

Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.162 enrolled3 locationsNCT06424665
Recruiting
Phase 1

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Small Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine CancerMetastatic or Locally Advanced Neuroendocrine Prostate Cancer+5 more
SystImmune Inc.120 enrolled20 locationsNCT07080242
Recruiting
Phase 1

DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer Extensive StageLarge Cell Neuroendocrine Carcinoma of the Lung
Legend Biotech USA Inc41 enrolled4 locationsNCT05680922
Recruiting
Phase 2

FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum

Large Cell Neuroendocrine Carcinoma of the Lung
Centre Leon Berard80 enrolled31 locationsNCT06393816
Recruiting
Phase 1

SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma

Recurrent/Refractory Small Cell Lung Cancer Lung Large Cell Neuroendocrine Carcinoma
Shanghai Simnova Biotechnology Co.,Ltd.35 enrolled1 locationNCT06384482